Cargando…
Antibody response to BNT162b2 SARS-CoV-2 mRNA vaccine in adult patients with systemic sclerosis
OBJECTIVES: Systemic sclerosis (SSc) patients are at risk for a severe disease course during SARS-CoV-2 infection either due to comorbidities or immunosuppression. The availability of SARS-CoV-2 vaccines is crucial for the prevention of this hard-to-treat illness. The aim of this study is to assess...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9132599/ https://www.ncbi.nlm.nih.gov/pubmed/35614287 http://dx.doi.org/10.1007/s10067-022-06219-7 |
_version_ | 1784713413908234240 |
---|---|
author | Pellicano, Chiara Campagna, Roberta Oliva, Alessandra Leodori, Giorgia Miglionico, Marzia Colalillo, Amalia Mezzaroma, Ivano Mastroianni, Claudio Maria Turriziani, Ombretta Rosato, Edoardo |
author_facet | Pellicano, Chiara Campagna, Roberta Oliva, Alessandra Leodori, Giorgia Miglionico, Marzia Colalillo, Amalia Mezzaroma, Ivano Mastroianni, Claudio Maria Turriziani, Ombretta Rosato, Edoardo |
author_sort | Pellicano, Chiara |
collection | PubMed |
description | OBJECTIVES: Systemic sclerosis (SSc) patients are at risk for a severe disease course during SARS-CoV-2 infection either due to comorbidities or immunosuppression. The availability of SARS-CoV-2 vaccines is crucial for the prevention of this hard-to-treat illness. The aim of this study is to assess the humoral response after mRNA vaccination against SARS-CoV-2 in SSc patients. METHOD: Seropositivity rate and serum IgG levels were evaluated 1 month (t1) and 3 months (t3) after the second dose of vaccine in a cohort of SSc patients and healthy controls (HC). Differences were made with Student’s or Mann–Whitney’s t-test and with the chi-square or Fisher exact test. Logistic regression model including immunosuppressive treatments (corticosteroids, CCS; mycophenolate mofetil, MMF; methotrexate, MTX; rituximab, RTX) was built to assess the predictivity for seropositivity. RESULTS: The seropositivity rate was similar in 78 SSc patients compared to 35 HC at t1 but lower at t3. SSc patients had lower serum IgG levels than HC at t1 but not at t3. SSc patients treated with immunosuppressive therapy showed both a lower seropositive rate (t1, 90.3% vs 100%; t3, 87.1% vs 97.9%; p < 0.05) and serum IgG levels than untreated patients both at t1 [851 BAU/ml (IQR 294–1950) vs 1930 BAU/ml (IQR 1420–3020); p < 0.001] and t3 [266 BAU/ml (IQR 91.7–597) vs 706 BAU/ml (IQR 455–1330); p < 0.001]. In logistic regression analysis, only MTX was significant [OR 39.912 (95% CI 1.772–898.728); p < 0.05]. CONCLUSIONS: SSc patients treated with MTX had a lower serological response to mRNA vaccine, and even low doses of CCS can adversely affect antibody titer and vaccination response. |
format | Online Article Text |
id | pubmed-9132599 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-91325992022-05-26 Antibody response to BNT162b2 SARS-CoV-2 mRNA vaccine in adult patients with systemic sclerosis Pellicano, Chiara Campagna, Roberta Oliva, Alessandra Leodori, Giorgia Miglionico, Marzia Colalillo, Amalia Mezzaroma, Ivano Mastroianni, Claudio Maria Turriziani, Ombretta Rosato, Edoardo Clin Rheumatol Original Article OBJECTIVES: Systemic sclerosis (SSc) patients are at risk for a severe disease course during SARS-CoV-2 infection either due to comorbidities or immunosuppression. The availability of SARS-CoV-2 vaccines is crucial for the prevention of this hard-to-treat illness. The aim of this study is to assess the humoral response after mRNA vaccination against SARS-CoV-2 in SSc patients. METHOD: Seropositivity rate and serum IgG levels were evaluated 1 month (t1) and 3 months (t3) after the second dose of vaccine in a cohort of SSc patients and healthy controls (HC). Differences were made with Student’s or Mann–Whitney’s t-test and with the chi-square or Fisher exact test. Logistic regression model including immunosuppressive treatments (corticosteroids, CCS; mycophenolate mofetil, MMF; methotrexate, MTX; rituximab, RTX) was built to assess the predictivity for seropositivity. RESULTS: The seropositivity rate was similar in 78 SSc patients compared to 35 HC at t1 but lower at t3. SSc patients had lower serum IgG levels than HC at t1 but not at t3. SSc patients treated with immunosuppressive therapy showed both a lower seropositive rate (t1, 90.3% vs 100%; t3, 87.1% vs 97.9%; p < 0.05) and serum IgG levels than untreated patients both at t1 [851 BAU/ml (IQR 294–1950) vs 1930 BAU/ml (IQR 1420–3020); p < 0.001] and t3 [266 BAU/ml (IQR 91.7–597) vs 706 BAU/ml (IQR 455–1330); p < 0.001]. In logistic regression analysis, only MTX was significant [OR 39.912 (95% CI 1.772–898.728); p < 0.05]. CONCLUSIONS: SSc patients treated with MTX had a lower serological response to mRNA vaccine, and even low doses of CCS can adversely affect antibody titer and vaccination response. Springer International Publishing 2022-05-26 2022 /pmc/articles/PMC9132599/ /pubmed/35614287 http://dx.doi.org/10.1007/s10067-022-06219-7 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article Pellicano, Chiara Campagna, Roberta Oliva, Alessandra Leodori, Giorgia Miglionico, Marzia Colalillo, Amalia Mezzaroma, Ivano Mastroianni, Claudio Maria Turriziani, Ombretta Rosato, Edoardo Antibody response to BNT162b2 SARS-CoV-2 mRNA vaccine in adult patients with systemic sclerosis |
title | Antibody response to BNT162b2 SARS-CoV-2 mRNA vaccine in adult patients with systemic sclerosis |
title_full | Antibody response to BNT162b2 SARS-CoV-2 mRNA vaccine in adult patients with systemic sclerosis |
title_fullStr | Antibody response to BNT162b2 SARS-CoV-2 mRNA vaccine in adult patients with systemic sclerosis |
title_full_unstemmed | Antibody response to BNT162b2 SARS-CoV-2 mRNA vaccine in adult patients with systemic sclerosis |
title_short | Antibody response to BNT162b2 SARS-CoV-2 mRNA vaccine in adult patients with systemic sclerosis |
title_sort | antibody response to bnt162b2 sars-cov-2 mrna vaccine in adult patients with systemic sclerosis |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9132599/ https://www.ncbi.nlm.nih.gov/pubmed/35614287 http://dx.doi.org/10.1007/s10067-022-06219-7 |
work_keys_str_mv | AT pellicanochiara antibodyresponsetobnt162b2sarscov2mrnavaccineinadultpatientswithsystemicsclerosis AT campagnaroberta antibodyresponsetobnt162b2sarscov2mrnavaccineinadultpatientswithsystemicsclerosis AT olivaalessandra antibodyresponsetobnt162b2sarscov2mrnavaccineinadultpatientswithsystemicsclerosis AT leodorigiorgia antibodyresponsetobnt162b2sarscov2mrnavaccineinadultpatientswithsystemicsclerosis AT miglionicomarzia antibodyresponsetobnt162b2sarscov2mrnavaccineinadultpatientswithsystemicsclerosis AT colalilloamalia antibodyresponsetobnt162b2sarscov2mrnavaccineinadultpatientswithsystemicsclerosis AT mezzaromaivano antibodyresponsetobnt162b2sarscov2mrnavaccineinadultpatientswithsystemicsclerosis AT mastroianniclaudiomaria antibodyresponsetobnt162b2sarscov2mrnavaccineinadultpatientswithsystemicsclerosis AT turrizianiombretta antibodyresponsetobnt162b2sarscov2mrnavaccineinadultpatientswithsystemicsclerosis AT rosatoedoardo antibodyresponsetobnt162b2sarscov2mrnavaccineinadultpatientswithsystemicsclerosis |